CRXTW News and Press, Clarus Therapeutics Holdings Inc. Warrant 9/9/2026 From 10/26/21

JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Upon issuance, Clarus plans to list these patents in FDA’s ...

JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Ho...

NORTHBROOK, Ill., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present at th...

Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases An estimated 1 in 5,000 adults worldwide ...

NORTHBROOK, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will pre...